Trial Profile
A Multicenter, Randomized, Phase 2, Double-blind, Vehicle-controlled, Parallel Group Comparison Study to Evaluate the Safety and Efficacy of Q301 Cream in Adolescents and Adults With Mild to Moderate Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2020
Price :
$35
*
At a glance
- Drugs Q 301 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Qurient Co
- 21 Apr 2020 Status changed from recruiting to completed.
- 19 Nov 2019 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.
- 19 Nov 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Feb 2020.